11 news items
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
: 4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical
4sr 9k7bn8ey
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
dnkkjnfkmo00nitdgc33dkc
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
juow tuq8x76n5ymvbafwqdbv60pykz2rgb5sg9ituwfg60
TAK
13 Mar 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
9pqcu6ixsv0yvcn6zmbz0naxl607eoz2lt5lhb68s9h3jqm3m2p1ky3
TAK
26 Feb 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
ajxec 7bi0d627pj1m8h5dwxf
TAK
26 Feb 24
&, NYSE:TAK), a global, values-based, R&D-driven biopharmaceutical leader
7d7ravl 2onhxgk000okwiyom8ydq
TAK
13 Feb 24
to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people, and the planet. Takeda focuses its R&D efforts
- Prev
- 1
- Next